«Molecule identified that helps give resident T cells in the skin their anti-cancer punch: The molecule CD103 is key to the long - term residence of T cells in the skin and to their potent anti-tumor
response against melanoma.»
The Dartmouth team, led by Mary Jo Turk, Ph.D., established the crucial role of resident memory T cells in the skin in eliciting a strong protective
response against melanoma.
We assess spontaneous and vaccine - induced immune
responses against melanoma, and have a particular interest in developing methods for understanding functional subpopulations within melanoma and the optimal ways of targeting them therapeutically.
Two clinical trials that used antibodies to block PD - 1 and PD - L1, a related molecule that binds to PD - 1, resulted in significant and long lasting
responses against melanoma skin cancer, renal cell (kidney) cancer, and lung cancer.
Not exact matches
The first such drug, called ipilimumab (Yervoy), developed out of Allison's basic science research, showed much lower
response rates
against advanced
melanoma than those obtained with targeted drugs, but long - term follow - up found that 22 percent of those treated with Yervoy survived at least four years, unprecedented results for the disease.
Discuss how mouse models can be used to study human immune
responses against leukemia (using primary or genetically modified leukemia cells) and
melanoma
They used the gene - editing CRISPR / Cas9 technique to sift the genomes of
melanoma cells for changes that made tumors resistant to being killed by immune T cells, which are the main actors in the immune system
response against infections and cancer cells.
He adds, «This study was actually a pilot project for a much larger effort within the Center for Molecular Therapeutics to map
responses against drug combinations across hundreds of cancer cell lines, not just
melanoma, and look for novel combinations that will benefit subsets of patients regardless of the particular type of tumor they have.
If
melanoma cells can be made to produce IL - 2, this should stimulate a strong, specific immune
response against them.
As with the CTL4 brake, disabling PD - 1 can have dramatic effects
against melanoma and several other types of cancer, but again, the
response is far from universal.